Curr Med Res Opin. 2010 Feb;26(2):439-43. doi: 10.1185/03007990903512396.
Abstract Recent guidelines recommend strict goals for low-density lipoprotein cholesterol (LDL-C) (1.8-2.6 mmol/L; 70-100 mg/dL). However, these goals are not always met and many primary and secondary prevention patients are not optimally controlled. Both the under-prescription of lipid-lowering medication and lack of adherence to prescribed medications could account for this situation. In this issue of the journal, two studies evaluated the under-treatment of hypercholesterolemia in European countries, as well as patient/physician characteristics that are related to poor control of LDL-C. This editorial considers the implications of these findings. While we have come far in recent years in terms of treating hypercholesterolemia, we still have considerable room for improvement and progress towards evidence-based clinical practice.
摘要 最近的指南建议将低密度脂蛋白胆固醇（LDL-C）的目标值设定得非常低（1.8-2.6mmol/L；70-100mg/dL）。然而，这些目标值并非总能达到，许多一级和二级预防患者的 LDL-C 并未得到最佳控制。降脂药物的低使用率和对医嘱的不遵行都可能是造成这种情况的原因。在本期杂志中，两项研究评估了欧洲国家高胆固醇血症的治疗不足情况，以及与 LDL-C 控制不佳相关的患者/医生特征。本文社论考虑了这些发现的意义。虽然近年来我们在治疗高胆固醇血症方面取得了很大进展，但在朝着循证临床实践的方向前进时，我们仍有很大的改进和进步空间。
